On December 19, 2023, AC Immune SA, a Swiss clinical stage biopharmaceutical company pioneering in precision medicine for neurodegenerative diseases listed on the Nasdaq (Nasdaq: ACIU) completed an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share.

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately USD 50.1 m. The offering was made pursuant to an effective shelf registration statement of AC Immune SA previously filed with the U.S. Securities and Exchange Commission. Jefferies LLC and Leerink Partners LLC acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.

Homburger advised Jefferies LLC and Leerink Partners LLC with respect to matters of Swiss law. The Homburger team consisted of Benjamin Leisinger and Daniel Junginger (both Capital Markets).